Shuttle Pharmaceuticals Announces Pricing of $4.25 Million Private Placement Priced At-the-Market

Group 1 - Shuttle Pharmaceuticals Holdings, Inc. has entered into a securities purchase agreement with an accredited investor for gross proceeds of $4.25 million, intended for acquisitions, marketing, and general corporate purposes [1][2]. - The company will issue 1,180,877 shares of common stock at a purchase price of $3.60 per share, with the offering expected to close around June 23, 2025 [2][3]. - WestPark Capital, Inc. is acting as the exclusive placement agent for the offering, with additional details to be filed in a Form 8-K with the SEC [3]. Group 2 - Shuttle Pharmaceuticals is focused on improving outcomes for cancer patients treated with radiation therapy by developing therapies that enhance the effectiveness of radiation while minimizing side effects [6]. - The company's mission includes increasing cancer cure rates, prolonging patient survival, and improving quality of life through the development of radiation sensitizers [6].